SymBio Pharmaceuticals Limited (TYO:4582)
Japan · Delayed Price · Currency is JPY 173.00
+1.00 (0.58%)
Jul 17, 2025, 11:27 AM JST
SymBio Pharmaceuticals Revenue
SymBio Pharmaceuticals had revenue of 264.02M JPY in the quarter ending March 31, 2025, a decrease of -55.78%. This brings the company's revenue in the last twelve months to 2.12B, down -54.35% year-over-year. In the year 2024, SymBio Pharmaceuticals had annual revenue of 2.45B, down -56.13%.
Revenue (ttm)
2.12B
Revenue Growth
-54.35%
P/S Ratio
3.95
Revenue / Employee
19.62M
Employees
108
Market Cap
8.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.45B | -3.14B | -56.13% |
| Dec 31, 2023 | 5.59B | -4.42B | -44.15% |
| Dec 31, 2022 | 10.01B | 1.75B | 21.21% |
| Dec 31, 2021 | 8.26B | 5.27B | 176.42% |
| Dec 31, 2020 | 2.99B | 149.30M | 5.26% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,222.12B |
| Takeda Pharmaceutical Company | 4,581.55B |
| Daiichi Sankyo Company | 1,886.26B |
| HOYA Corporation | 866.03B |
| Terumo | 1,036.17B |
| Otsuka Holdings | 2,393.18B |
| Astellas Pharma | 1,912.32B |
| Shionogi & | 438.27B |